Literature DB >> 27544596

Short-term and long-term prognostic outcomes of patients with ST-segment elevation myocardial infarction complicated by profound cardiogenic shock undergoing early extracorporeal membrane oxygenator-assisted primary percutaneous coronary intervention.

Sheng-Ying Chung1, Meng-Shen Tong1, Jiunn-Jye Sheu2, Fan-Yen Lee2, Pei-Hsun Sung1, Chien-Jen Chen1, Cheng-Hsu Yang1, Chiung-Jen Wu1, Hon-Kan Yip3.   

Abstract

BACKGROUND: This study investigated the 30-day and long-term prognostic outcomes in patients with ST-segment elevation myocardial infarction (STEMI) complicated with profound cardiogenic shock (CS) undergoing early routine extracorporeal membrane oxygenator (ECMO)-assisted primary percutaneous coronary intervention (PCI).
METHODS: Between December 2005 and December 2014, 65 consecutive STEMI patients with profound CS underwent routine ECMO-supported primary PCI.
RESULTS: The incidences of acute pulmonary edema, respiratory failure with requirement of mechanical ventilatory support upon presentation, and 30-day mortality rate were 100%, 95.4%, and 43.1%, respectively. The duration of hospitalization, mean long-term follow-up, and survival rate were 32.1±53.1 (days), 733.6±986.7 (days), and 32.3%, respectively. The mean APACHE score (32.6±8.3 vs. 28.5±7.5), peak serum creatinine level (4.3±2.4 vs. 1.7±1.2mg/dL), incidences of failed ECMO weaning (57.1% vs. 0%), successful ECMO weaning but in-hospital death (40.0% vs. 0%) were significantly lower in 30-day survivors than those in non-survivors (all p<0.05), whereas final thrombolysis in myocardial infarction (TIMI)-3 flow [53.6% vs. 91.9%] showed an opposite pattern compared to that of APACHE score in the two groups (p<0.02). Multivariate analysis demonstrated that unsuccessful reperfusion, failed ECMO weaning, and peak creatinine level were independent predictors of 30-day mortality (all p<0.01).
CONCLUSIONS: Early ECMO-supported primary PCI in STEMI patients with profound CS was feasible as a life-saving strategy with acceptable 30-day and long-term prognostic outcomes.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Extracorporeal membrane oxygenator support; Primary percutaneous coronary intervention; Profound cardiogenic shock; Short-term and long-term outcomes

Mesh:

Year:  2016        PMID: 27544596     DOI: 10.1016/j.ijcard.2016.08.068

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  15 in total

1.  Predictors of Survival for Patients with Acute Decompensated Heart Failure Requiring Extra-Corporeal Membrane Oxygenation Therapy.

Authors:  A Reshad Garan; Waqas A Malick; Marlena Habal; Veli K Topkara; Justin Fried; Amirali Masoumi; Aws K Hasan; Dimitri Karmpaliotis; Ajay Kirtane; Melana Yuzefpolskaya; Maryjane Farr; Yoshifumi Naka; Dan Burkhoff; Paolo C Colombo; Paul Kurlansky; Hiroo Takayama; Koji Takeda
Journal:  ASAIO J       Date:  2019 Nov/Dec       Impact factor: 2.872

2.  Could Selective Re-look Angiography Improve the Outcome of Cardiogenic Shock in Patients Under Veno-arterial Extracorporeal Membrane Oxygenator?

Authors:  Maurice Maksoud; Amr S Omar; Praveen Sivadasan; Tamer Abdalghafoor; Alaa Rahhal; Tasnim Abdalla; Bassam Shoman; Rula Taha; Abdulaziz AlKhulaifi
Journal:  J Cardiovasc Transl Res       Date:  2022-01-24       Impact factor: 3.216

3.  Extracorporeal Membrane Oxygenation Use in Acute Myocardial Infarction in the United States, 2000 to 2014.

Authors:  Saraschandra Vallabhajosyula; Abhiram Prasad; Malcolm R Bell; Gurpreet S Sandhu; Mackram F Eleid; Shannon M Dunlay; Gregory J Schears; John M Stulak; Mandeep Singh; Bernard J Gersh; Allan S Jaffe; David R Holmes; Charanjit S Rihal; Gregory W Barsness
Journal:  Circ Heart Fail       Date:  2019-12-12       Impact factor: 8.790

4.  Veno-arterial extracorporeal membrane oxygenation in addition to primary PCI in patients presenting with ST-elevation myocardial infarction.

Authors:  F S van den Brink; A D Magan; P G Noordzij; C Zivelonghi; P Agostoni; F D Eefting; J M Ten Berg; M J Suttorp; B R Rensing; J P van Kuijk; P Klein; E Scholten; J A S van der Heyden
Journal:  Neth Heart J       Date:  2018-02       Impact factor: 2.380

5.  Platelet-, monocyte-derived and tissue factor-carrying circulating microparticles are related to acute myocardial infarction severity.

Authors:  Gemma Chiva-Blanch; Kristian Laake; Peder Myhre; Vibeke Bratseth; Harald Arnesen; Svein Solheim; Lina Badimon; Ingebjørg Seljeflot
Journal:  PLoS One       Date:  2017-02-16       Impact factor: 3.240

Review 6.  Predictors of Outcomes in Myocardial Infarction and Cardiogenic Shock.

Authors:  Deepak Acharya
Journal:  Cardiol Rev       Date:  2018 Sep/Oct       Impact factor: 2.644

7.  Outcomes of Coronary Artery Bypass Grafting after Extracorporeal Life Support in Patients with Cardiac Arrest or Cardiogenic Shock.

Authors:  Younghwan Kim; Yang-Hyun Cho; Ji-Hyuk Yang; Kiick Sung; Young Tak Lee; Wook Sung Kim; Heemoon Lee; Su Hyun Cho
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2019-04-05

8.  Effect of interplay between age and low-flow duration on neurologic outcomes of extracorporeal cardiopulmonary resuscitation.

Authors:  Hsi-Yu Yu; Chih-Hsien Wang; Nai-Hsin Chi; Shu-Chien Huang; Heng-Wen Chou; Nai-Kuan Chou; Yih-Sharng Chen
Journal:  Intensive Care Med       Date:  2018-12-13       Impact factor: 17.440

Review 9.  Overview of Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO) Support for the Management of Cardiogenic Shock.

Authors:  Adamantios Tsangaris; Tamas Alexy; Rajat Kalra; Marinos Kosmopoulos; Andrea Elliott; Jason A Bartos; Demetris Yannopoulos
Journal:  Front Cardiovasc Med       Date:  2021-07-07

10.  Relationship between Clinical Outcomes and Cardiopulmonary Resuscitation Time in Patients with Acute Myocardial Infarction Treated by Extracorporeal Membrane Oxygenation-Assisted Primary Percutaneous Coronary Intervention.

Authors:  Sungsoo Cho; Wonkyung Lee; Seong Hoon Lim; Tae Soo Kang
Journal:  Korean Circ J       Date:  2018-08       Impact factor: 3.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.